PARP and PARG inhibitors in cancer treatment [PDF]
Genes & Development, 2020 Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying genomic instability through radiotherapy and chemotherapy has been a powerful but nonselective means of killing cancer cells. Precision medicine has revolutionized cancer therapy by putting forth the concept of selective targeting of cancer cells. Poly(ADP-ribose)
openaire +2 more sources
Role of PARylation and PTEN Mutation on PARP and PARG Inhibitor Efficacy on Glioblastoma [PDF]
, 2020 Abstract Glioblastoma (GBM) is the most aggressive primary adult brain tumor, with a median survival of approximately 15 months. Despite novel therapeutic approaches, median survival has remained largely unchanged since the standard of care therapy for GBM was established nearly 15 years ago.
Henre Hermanowski +4 more
openaire +1 more source
Poly(ADP-ribosylation) is present in murine sciatic nerve fibers and is altered in a Charcot-Marie-Tooth-1E neurodegenerative model [PDF]
PeerJ, 2017 Background Poly-ADP-ribose (PAR) is a polymer synthesized by poly-ADP-ribose polymerases (PARPs) as a postranslational protein modification and catabolized mainly by poly-ADP-ribose glycohydrolase (PARG).
Laura I. Lafon Hughes +7 more
doaj +2 more sources
Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors [PDF]
Cancer Research, 2017 Abstract The majority of pancreatic ductal adenocarcinomas (PDAC) rely on the mRNA stability factor HuR (ELAV-L1) to drive cancer growth and progression. Here, we show that CRISPR-Cas9–mediated silencing of the HuR locus increases the relative sensitivity of PDAC cells to PARP inhibitors (PARPi).
Chand, Saswati N. +17 more
openaire +2 more sources
Unrestrained poly-ADP-ribosylation provides insights into chromatin regulation and human disease [PDF]
, 2021 ARH3/ADPRHL2 and PARG are the primary enzymes reversing ADP-ribosylation in vertebrates, yet their functions in vivo remain unclear. ARH3 is the only hydrolase able to remove serine-linked mono(ADP-ribose) (MAR) but is much less efficient than PARG ...
Wondisford, Anne R. +9 more
core +3 more sources
PARP and PARG Inhibitors—New Therapeutic Targets in Cancer Treatment
Pathology & Oncology Research, 2010 Today, the number of cancer patients throughout the world is increasing alarmingly and as per the World Health Organisation (WHO) data and statistics the prediction for the year 2020 will be 15 million new cases as compared to only 10 million cases in year 2000 leaving us dumbfounded.
Nilufer Jasmine Selimah, Fauzee +2 more
openaire +2 more sources
Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib [PDF]
, 2018 Upon DNA binding the poly(ADP-ribose) polymerase family of enzymes (PARPs) add multiple ADP-ribose subunits to themselves and other acceptor proteins.
Gravells, P. +20 more
core +1 more source
In Vivo Level of Poly(ADP-ribose)
Challenges, 2018 PolyADP-ribosylation is a post-translational modification that plays key roles in cellular physiological functions and DNA damage responses. PolyADP-ribosylation is finely and dynamically regulated by various enzymes and factors involved in the synthesis
Masanao Miwa +9 more
doaj +1 more source
ROS-Specific Huntingtin Interactions: Testing PARG activity in HD patient fibroblasts
, 2019 Comparison nuclear PAR levels in wild type and HD (TruHD) fibroblasts in response to a PARG inhibitor concentration gradient (as a measure of PARG activity).
Maiuri, Tamara +3 more
core +1 more source
, 2014 Poly(ADP-ribosyl)ation is involved in numerous bio-logical processes including DNA repair, transcription and cell death. Cellular levels of poly(ADP-ribose) (PAR) are regulated by PAR polymerases (PARPs) and the degrading enzyme PAR glycohydrolase (PARG),
Noll, Aurélia +7 more
core +2 more sources